

CLAIM AMENDMENTS

This listing of claims will replace all prior versions and listings of the claims in the application.

1-58. (Cancelled)

59. (Currently amended) A pharmaceutical composition comprising an agent for suppressing an immune response ~~and at least one agent selected from the group consisting of an EGF receptor ligand and a gastrin/CCK receptor ligand~~ wherein the agent is a rapamycin and the gastrin is gastrin17Leu15.

60.-65. (Cancelled)

66. (Original) The composition according to claim 59, ~~wherein the agent for suppressing immune response is at least one selected from of the group consisting of a rapamycin; a corticosteroid; an azathioprine; mycophenolate mofetil; a cyclosporine; a cyclophosphamide; a methotrexate; a 6-mercaptopurine; FK506 (further comprising Tacrolimus); 15-deoxyspergualin; an FTY 720; a mitoxantrone; a 2-amino-1,3-propanediol; a 2-amino-2-(4-oethylphenyl)ethylpropane-1,3-diol hydrochloride; a 6-(3-dimethyl-aminopropionyl)-forskolin; and a demethimmunomycin.~~

67-77. (Cancelled)

78. (Currently Amended) A method of treating a diabetic subject comprising administering to said subject an agent that increases islet neogenesis and an agent that suppresses an immune response, wherein said agent that increases islet neogenesis is ~~an EGF receptor ligand or a gastrin/cholecystekinin (CCK) receptor ligand~~ gastrin17Leu15 and said agent that suppresses an immune response is a rapamycin.

79.-83. (Cancelled)

84. (Currently Amended) The method according to claim 78, wherein said agent that suppresses an immune response is an agent selected from of the group consisting of ABX-CBL, Alefacept, allotrap HLA-B270, antithymocyte immunoglobulin, ATGAM, azathioprine, basiliximab, BTI-322, cyclophosphamide, cyclosporine, daclizumab, demethimmunomycin, efalizumab, Enlimomab, Everolimus, FK506 (further comprising administering Tacrolimus), FTY 720, hul 124, infliximab, interferon, ISAtx247, Medi-500, Medi-507, methotrexate, mitoxantrone, mycophenolate mofetil, OKT3, OKT4A, rapamycin, Sirolimus, 2-amino-1,3-propanediol, 2-amino-2[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride, 6-mercaptopurine, 6-(3-dimethyl-aminopropionyl) forskolin, and 15-deoxyspergualin.

85. (Cancelled)

86. (Previously Presented) The method according to claim 78, wherein said agent that increases islet neogenesis and said agent that suppresses an immune response are administered sequentially.

87. (Previously Presented) The method according to claim 78, wherein the subject is a human.

88. (Cancelled)

89. (Previously Presented) The method according to claim 78, wherein the diabetic subject has recent onset diabetes.

90. (Cancelled)